source
- Vanda pauses social anxiety program after Phase 3 trial misses endpoint in womenVanda Pharmaceuticals announced Wednesday that it is halting development of its social anxiety disorder candidate after a late-stage trial did not achieve its primary goal. The experimental drug,…
- Nvidia-backed Iambic Therapeutics raises $150M in IPO, begins trading ThursdayIambic Therapeutics, a biotech focused on using artificial intelligence to develop cancer treatments, announced the completion of its initial public offering. The company sold 9.38 million shares…